Dilutive Acquisition
A dilutive acquisition lowers the buyer's earnings per share: the target's earnings, net of synergies and the cost of financing, add less to profit than the new shares or interest take away — usually because the target was bought at a higher earnings multiple than the buyer's own, or because it does not yet earn much. It is what a bank buying a fast-growing fintech usually announces, and the announcement is a statement about growth, not a confession.
- Also known as
- Dilution, EPS-dilutive deal, Dilutive deal
- Used at
- acquisitions of high-growth or loss-making targets by lower-multiple buyers; almost every incumbent's purchase of a fintech scale-up
- Binding
- no — a forecast; the board's paper shows the year in which the deal turns accretive and the shareholders hold it to that
- Typical arithmetic
- dilutive when the target's earnings yield (earnings ÷ price) is below the buyer's cost of financing — a target at 30× earnings yields 3.3%, which no share issue at 12× (an 8.3% yield) and few debt packages can beat
- Typical justification
- growth that the buyer's own business cannot produce; a licence, a platform or a capability that would cost more to build; defensive — the target in a competitor's hands would cost more than dilution
- Parties
- the buyer's board and shareholders, the analysts who model the EPS, and the target, whose price the buyer's multiple constrains
How dilution works in practice
A bank earning €2.00 a share on a 12× multiple looks at a payments fintech growing 40% a year, earning €20m, priced at 35× — €700m. Paying in shares means issuing €700m of stock at 12× earnings — stock that "earns" €58m a year for the bank's shareholders — to buy a business earning €20m: the deal is dilutive by a wide margin on day one and stays dilutive until the fintech's earnings pass what the issued shares would have earned, which at 40% growth is about three years. Paying in cash at 5% costs €35m of interest to acquire €20m of earnings: also dilutive.
Boards do the deal anyway when the alternative is worse. The bank's own earnings are flat; the fintech's growth is what its shareholders lack; the capability would cost €300m and four years to build; a competitor is also bidding. The board paper shows the dilution by year, the crossover, and the return on invested capital, which is the number that actually matters — a dilutive deal can earn well above the cost of capital if the growth arrives, and an accretive one can fail to.
The market's reaction to a dilutive announcement depends on whether it believes the growth. Announced with a credible plan, the shares hold; announced with a synergy number that looks like a plug, they fall, and the board spends the next two years proving the crossover year.
Example
A payments incumbent earning €300m on 150m shares (€2.00; 14×, shares at €28) buys a fintech with €80m of revenue growing 45% and €8m of earnings, for €900m in shares — 32m new shares. Year one: €308m + €5m of synergies on 182m shares, €1.72 — 14% dilutive. Year three, if the plan holds (revenue €170m, earnings €45m, synergies €20m): €365m on 182m shares, €2.01 — accretive. The board announces the crossover in year three; the shares fall 6% on the day and recover in eighteen months as the fintech's quarterly numbers land. Had the incumbent waited two years and bought the same company at €1.6bn, the dilution would have been deeper and the crossover later — the case for dilution was that the price was going up.
Common mistakes
- Refusing a dilutive deal on EPS alone, and losing the target to a competitor whose shareholders understood growth. - Announcing a crossover year without a plan that produces it. - Hiding dilution behind "adjusted" earnings that exclude the amortisation the deal creates. - Modelling the target's growth without the churn an acquisition causes. - Confusing dilution of earnings per share with dilution of value; a dilutive deal at a fair price for real growth creates value, and a market that punishes it is a market to explain to, not to obey.